Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylateStefanos Labropoulos, Evangelia Razis, Jonathan A. Fletcher et al.|Anti-Cancer Drugs|2005Cited by 104
Phase II Study of Neoadjuvant Imatinib in Glioblastoma: Evaluation of Clinical and Molecular Effects of the TreatmentEvangelia Razis, George Fountzilas, Panayotis Selviaridis et al.|Clinical Cancer Research|2009Cited by 103
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancerGiannis Mountzios, Petros Christopoulos, Mariam Elshiaty et al.|ESMO Open|2021Cited by 93
Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology GroupHelena Linardou, George Fountzilas, Nikolaos Spanakis et al.|Cancers|2021Cited by 41
Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology GroupElena Fountzilas, G. Koumakis, Georgia-Angeliki Koliou et al.|ESMO Open|2020Cited by 38